Skip to Content
Merck
CN

SML4009

Zuclopenthixol decanoate

≥98% (HPLC)

Synonym(s):

Decanoic acid 2-[4-[(3Z)-3-(2-chloro-9H-thioxanthen-9-ylidene)propyl]-1-piperazinyl]ethyl ester

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C32H43ClN2O2S
CAS Number:
64053-00-5
Molecular Weight:
555.21
UNSPSC Code:
12352116
MDL number:
MFCD03792797
NACRES:
NA.21
Assay:
≥98% (HPLC)
Form:
oil
Quality level:
100

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI

1S/C32H43ClN2O2S/c1-2-3-4-5-6-7-8-15-32(36)37-24-23-35-21-19-34(20-22-35)18-11-13-27-28-12-9-10-14-30(28)38-31-17-16-26(33)25-29(27)31/h9-10,12-14,16-17,25H,2-8,11,15,18-24H2,1H3/b27-13-

InChI key

QRUAPADZILXULG-WKIKZPBSSA-N

SMILES string

ClC(C=C1)=CC2=C1SC3=CC=CC=C3/C2=C/CCN4CCN(CCOC(CCCCCCCCC)=O)CC4

assay

≥98% (HPLC)

form

oil

color

, Colorless to light brown

storage temp.

-10 to -25°C

Quality Level

100

Biochem/physiol Actions

Long-lasting injectable formulation (depot form) of Zuclopenthixol; potent antagonist of D1/D2 dopamine receptors, α1-adrenergic receptors and 5-HT2 receptors.

Zuclopenthixol decanoate is a long-lasting injectable formulation (depot form) of Zuclopenthixol. Zuclopenthixol decanoate is a potent antagonist of D1/D2 dopamine receptors, α1-adrenergic receptors and 5-HT2 receptors. Zuclopenthixol decanoate is approved in some countries for treatment of schizophrenia and other psychoses and recommended for patients who are agitated or aggressive.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Christoph U Correll et al.
CNS drugs, 35(1), 39-59 (2021-01-29)
The availability of long-acting injectable (LAI) antipsychotics for the treatment of schizophrenia provides clinicians with options that deliver continuous drug exposure and may improve adherence compared with daily oral antipsychotics. However, all LAI antipsychotics have unique formulations and pharmacokinetic characteristics
Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses
Cochrane database of systematic reviews (Online), 1999(2) (2000)
Matthew Cordiner et al.
Therapeutic advances in psychopharmacology, 6(2), 66-76 (2016-05-04)
Antipsychotic polypharmacy (APP) is common clinical practice. Theoretically, APP runs the risk of additional side effects, drug interactions, adherence and cost. A limited evidence base is emerging to support the effectiveness of APP in clinical practice. Our companion paper highlighted

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service